Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksODX.L Regulatory News (ODX)

  • There is currently no data for ODX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update and Notice of Results

25 Apr 2017 07:00

RNS Number : 1774D
Omega Diagnostics Group PLC
25 April 2017
 

 

Omega Diagnostics Group PLC

("Omega" or "the Company")

 

Trading Update and Notice of Results

 

Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces that results for the year to 31 March 2017 will be in line with market expectations. Revenues for the year are expected to be £14.3m and adjusted profit before tax* is expected to be £1.1m.

 

Financial update

 

Revenue is expected to be £14.25m, 3% ahead of last year in constant currency terms and 12% ahead of last year's result (31 March 2016: £12.74m) on an actual basis, reflecting the weakening of sterling against the US dollar and euro throughout the period.

 

Segmental revenues are expected to be as follows:

 

 

Revenue to

31 March 2017

Revenue to

31 March 2016

 

% increase

Food Intolerance

£8.00m

£7.06m

+ 13%

Allergy/Autoimmune

£3.59m

£3.16m

+ 14%

Infectious Disease/Other

£2.66m

£2.52m

+ 5%

TOTAL

£14.25m

£12.74m

+ 12%

 

 

Allergy development

IDS-iSYS automation update

We continue to have discussions with IDS on how best to commercialise our Allersys® range of reagents and believe we can achieve an outcome that will benefit both parties. The time taken on the discussions to date reflects the importance on achieving the right balance for both parties on what we anticipate will be a long term relationship. We will provide a further update in due course.

 

We have continued to develop the allergen range and we have now optimised a further nine allergens, in addition to the 41 allergens which are CE-Marked for use on the IDS-iSYS automated instrument.

 

Infectious disease

CD4 update

We confirm we have now attained formal design freeze with our VISITECT® CD4 test following the successful manufacture of three pilot batches. Devices from these batches were tested at three UK hospital sites, on sufficient numbers of patient samples to demonstrate that we now have a method for manufacturing devices which consistently meet our design goal specifications regarding sensitivity and specificity.

 

Achieving this significant milestone means we have now progressed into the formal verification and validation phase. We will use the chosen design to manufacture three validation batches which will be sent for field trial evaluation at selected sites in the UK and India. The field trial results, combined with a number of planned internal experiments to support product claims will, if successful, enable us to CE-Mark the test after conclusion of these activities.

 

Outlook

We have reached a significant milestone in achieving design freeze with our VISITECT® CD4 development programme. We remain confident in completing the verification and validation programme to deliver a unique product which we believe will meet a large unmet medical need for people living with HIV infections in resource-limited countries.

 

We have also been successful in achieving full operational capability with our manufacturing facility in Pune, India. Whilst we have already indicated we expect to achieve modest sales with our Malaria range of tests this year, we believe we have created a valuable asset which can grow shareholder value in the years ahead.

 

We are encouraged by the ongoing performance of our core business. Our Food Intolerance division continues to grow at a healthy rate and we are reviewing initiatives as to how we may grow this business in North America. Our allergy business in Germany achieved a 3% increase in euro denominated turnover, reversing a declining trend in recent years. The development updates we have outlined and the investments we have made in people and infrastructure give us much confidence for the future.

 

Omega expects to announce its financial results for the year ended 31 March 2017 by mid-July.

 

The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

* before share based payments, IFRS-related discount unwinds and amortisation of intangible assets

 

Contacts:

 

Omega Diagnostics Group PLC

Tel: 01259 763 030

Andrew Shepherd, Chief Executive

www.omegadiagnostics.com

Kieron Harbinson, Group Finance Director

 

Jag Grewal, Group Sales and Marketing Director

 

 

 

finnCap Ltd

Tel: 020 7220 0500

Geoff Nash/James Thompson (Corporate Finance)

 

Mia Gardner (Corporate Broking)

 

 

 

Walbrook PR Limited

Tel: 020 7933 8780 or omega@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBLGDSSDDBGRS
Date   Source Headline
6th Sep 20237:00 amRNSAGM Statement
1st Sep 202310:29 amRNSUpdate on proposed Share Reorganisation
31st Aug 20237:00 amRNSProposed Share Reorganisation Timetable
22nd Aug 20237:00 amRNSDirectorate Change
17th Aug 20237:00 amRNSBoard Appointment
15th Aug 20231:45 pmRNSDirector/PDMR Shareholding
14th Aug 20237:00 amRNSPosting of Annual Report and confirmation of AGM
3rd Aug 20237:00 amRNSFinal Results
27th Jul 20237:00 amRNSNotice of Results
26th Jul 20232:10 pmRNSHolding(s) in Company
6th Jun 202311:19 amRNSHolding(s) in Company
5th Jun 20234:51 pmRNSHolding(s) in Company
2nd Jun 20232:45 pmRNSHolding(s) in Company
22nd May 20235:33 pmRNSHolding(s) in Company
10th May 20237:00 amRNSBLOCK LISTING SIX MONTHLY RETURN
9th May 20233:42 pmRNSDirector/PDMR Shareholding
21st Apr 20239:48 amRNSHolding(s) in Company
19th Apr 20239:31 amRNSHolding(s) in Company
17th Apr 20237:00 amRNSTrading Update
22nd Mar 20235:57 pmRNSBlock Listing Six Monthly Return
22nd Mar 20233:00 pmRNSHolding(s) in Company
6th Mar 20232:31 pmRNSHolding(s) in Company
27th Jan 20233:03 pmRNSHolding(s) in Company
27th Jan 20239:36 amRNSDirector/PDMR Shareholding
18th Jan 20237:00 amRNSTrading update
16th Jan 202310:56 amRNSHolding(s) in Company
6th Jan 20237:00 amRNSUS expansion update
3rd Jan 202312:34 pmRNSHolding(s) in Company
13th Dec 20224:40 pmRNSSecond Price Monitoring Extn
13th Dec 20224:35 pmRNSPrice Monitoring Extension
13th Dec 202212:01 pmRNSHolding(s) in Company
30th Nov 20229:35 amRNSHolding(s) in Company
25th Nov 20227:00 amRNSReceipt of deferred consideration
24th Nov 20227:00 amRNSHalf-year Report
23rd Nov 20224:41 pmRNSSecond Price Monitoring Extn
23rd Nov 20224:36 pmRNSPrice Monitoring Extension
23rd Nov 20222:05 pmRNSSecond Price Monitoring Extn
23rd Nov 20222:00 pmRNSPrice Monitoring Extension
18th Nov 202212:09 pmRNSHolding(s) in Company
16th Nov 20222:06 pmRNSSecond Price Monitoring Extn
16th Nov 20222:00 pmRNSPrice Monitoring Extension
15th Nov 20227:00 amRNSConfirmation of Results and Investor Presentation
14th Nov 20227:00 amRNSPartnership agreement with Software Provider
8th Nov 20229:04 amRNSLaunch of new all-employee share incentive plan
26th Oct 20222:50 pmRNSResult of AGM
26th Oct 20227:00 amRNSAGM Statement and Notice of Results
11th Oct 20227:00 amRNSScientific Director to present at FIDHC
5th Oct 20227:00 amRNSPositive WHO data received for VISITECT® CD4 test
27th Sep 20227:00 amRNSPosting of Annual Report and confirmation of AGM
20th Sep 202212:05 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.